Hutchison China MediTech Ltd ("Chi-Med"):
Focused on discovering, developing and commercializing targeted therapeutics and immunotherapies in oncology and autoimmune diseases. It has a portfolio of eight cancer drug candidates currently in late stage clinical studies around the world. In November 2018, fruquintinib (Elunate) was commercially launched in China for the treatment of patients with metastatic colorectal cancer (CRC).
Marketed, Phase III, Phase l or ll
Anti-inflammatory, Autoimmune, Immunotherapy, Oncology
230 Park Ave
New York, NY 10169
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Upcoming Company Event Participation
Hamptons CEO Roundtable 2019
August 15, 2019
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by